Pharming Group N.V. ADS, each representing 10 ordinary shares
PHARPharming Group N.V. ADS is a biopharmaceutical company specializing in the development of innovative therapies for rare, unmet medical needs. The company focuses on producing recombinant protein therapies, including treatments for genetically defined diseases and conditions involving enzyme deficiencies. Pharming is known for its flagship product, Rapyda, used in the treatment of hereditary angioedema. The company's operations are centered around developing and commercializing biologic medicines for patients worldwide.
Company News
Pharming Group reported Q1 2026 revenues of US$72.4 million (8% decrease YoY), with RUCONEST® declining 15% due to anticipated inventory drawdowns and market exit, while Joenja® grew 34% YoY. The company resubmitted pediatric sNDA to FDA for Joenja® and received positive CHMP opinion for European approval. Pharming maintained 2026 revenue guid...
Pharming Group N.V. will report its preliminary Q1 2026 financial results and provide a business update on May 7, 2026, with a conference call and webcast for analysts and investors. The company will also hold its 2026 Annual General Meeting of Shareholders on May 28, 2026.
Pharming Group N.V. announced its participation in investor conferences in April 2026, including the Needham Virtual Healthcare Conference and Van Lanschot Kempen Life Sciences Conference. The company also announced a positive CHMP (Committee for Medicinal Products for Human Use) opinion for Joenja® (leniolisib) for treating APDS in adult and pe...
Pharming Group announced that Japan's Ministry of Health, Labour and Welfare has approved Joenja® (leniolisib) for treating APDS in patients aged 4 years and older. This marks the first approved treatment for APDS in Japan and the first global approval for children aged 4-11 with the disease. The approval was based on positive Phase III clinical...
Pomerantz Law Firm is investigating Pharming Group N.V. for potential securities fraud following the FDA's issuance of a Complete Response Letter rejecting the company's supplemental application for Joenja® (leniolisib) for pediatric patients. The FDA cited concerns about drug underexposure in lower weight patients and analytical method issues. ...
